Agomab Therapeutics (AGMB) said late Monday it closed its initial public offering of 12.5 million American depository shares at a public offering price of $16 per ADS, raising about $200 million in gross proceeds before underwriting fees and expenses.
The American depository shares started trading on the Nasdaq Global Select Market on Feb. 6.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.